View the latest price targets for CRSP. What is the current consensus analyst rating for CRISPR Therapeutics? CRISPR Therapeutics currently has 1 sell rating, 9 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating ...
Stay up-to-date with the latest CRSP US Consumer Discretionary Total Return Index (CRSPCDT:IND) stock price. View CRSPCDT:IND stock price chart and historical prices to make forecasts and predictions.
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. Continue with Google Continue with Apple or Create Free Account By creating an account using any of the options above, you agree to theTerms of Use&Privacy Policy ...
The screener displays probability calculations based on the delayed stock price at the time the strategy is updated. The new day's options data will start populating the screener at approximately 8:55a CT. Strikes that have not traded today are excluded from the results. Above the table, we ...
CRISPR Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results and Barclays Raised Its Price Target on the Stock From $55 to $56. BenzingaFeb 12 22:57 RBC Capital Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Cuts Target Price to $...
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. ...
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, CRISPR Therapeutic...
Spreads Protection Strategies Straddles & Strangles Horizontal Spreads Butterfly Spreads Condor Strategies company News & Headlines Key Statistics SEC Filings Competitors Stock Comparison Insider Trades analysts Earnings Estimates Analyst Ratings financials Financial Summary Income Statement Balance Sheet Cash Flow...
Why It Matters Interestingly, investor and entrepreneur Cathie Wood’sARK Innovation ETF(NASDAQ:ARKK)acquired more sharesof CRSP stock. In addition, Cantor Fitzgerald analyst Olivia Brayer recently initiated coverage of CRISPR with a “buy” rating. The expert’sprice target stands at $72, which im...
recommended for you about crsp stock symbol last price % chg 1d 5d 1m 6m 1y 5y 10y market cap pe yield rev growth (yoy) short interest prev. close compare to peers more on crsp related stocks symbol last price % chg crsp crsp - - 1d 5d 1m 6m 1y 5y 10y compare trending ...